FDA Approves Cancer Drug for Arthritis
Posted on: Wednesday, 1 March 2006, 12:00 CST
The U.S. Food and Drug Administration has approved a popular cancer-fighting drug for use by sufferers of rheumatoid arthritis.
Rituxan, an expensive treatment for cancer but easier on the body than chemotherapy, can now be marketed to the often debilitating arthritis, The Washington Post reports.
In rheumatoid arthritis joints are hit by the immune system and can start earlier in life than the common arthritis.
Rituxan is a genetically engineered antibody that, in some people, suppresses the immune cells causing rheumatoid arthritis.
Rituxan has raked in $1.8 billion in annual sales for California-based Genentech and Massachusetts-based Biogen Idec Inc. The cost for a year of Rituxan is $18,000 a patient.
Rituxan is being studied for its treatment of other immune diseases like lupus and multiple sclerosis.
Source: United Press International
Related Articles
- New Data Points to Long Lasting Beneficial Effects of CEL-SCI's Rheumatoid Arthritis Vaccine
- Rituxan Data in Patients With Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
- Data From Phase II Exploratory Study Suggest That ORENCIA(R) (Abatacept) May Delay Development of Rheumatoid Arthritis in Adults With Undifferentiated Inflammatory Arthritis
- FDA APPROVES RITUXAN(R) (Rituximab), FIRST B-CELL TARGETED TREATMENT FOR RHEUMATOID ARTHRITIS
- Clinical Trials
- Biogen Idec and Genentech Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for Rituxan(R) in Rheumatoid Arthritis
- HUMIRA(R) (Adalimumab) Approved in Europe for the Treatment of Psoriatic Arthritis and As a First-Line Treatment of Severe Rheumatoid Arthritis
- Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients With Rheumatoid Arthritis
- The 'Alphabet' of Rheumatoid Arthritis Treatment
 |
 |
User Comments (0)
RSS Feeds